CGRP-Blocking Antibodies Offer New Hope for Chronic and Episodic Migraine Prevention
Four monoclonal antibodies targeting CGRP — a peptide involved in migraine — show strong evidence for reducing migraine frequency with fewer side effects than older treatments.
Quick Facts
What This Study Found
All four anti-CGRP monoclonal antibodies demonstrated significant reductions in monthly migraine days across multiple Phase 2-3 clinical trials, with favorable safety profiles compared to existing preventive treatments.
Key Numbers
4 monoclonal antibodies; migraine is 2nd leading cause of disability; monthly or quarterly dosing
How They Did This
Narrative review of published clinical trial data, ongoing trials, and pharmacological evidence for CGRP-targeting monoclonal antibodies in episodic and chronic migraine prevention.
Why This Research Matters
Migraine is the second leading cause of disability worldwide, and many patients fail existing preventive treatments or stop taking them due to side effects. CGRP-targeting antibodies represent the first migraine-specific preventive therapy class.
The Bigger Picture
These CGRP-targeting therapies represent a shift from repurposed drugs (beta-blockers, antidepressants, anticonvulsants) to mechanism-based migraine treatments, reflecting advances in understanding neuropeptide signaling in headache disorders.
What This Study Doesn't Tell Us
Review format — no new trial data. Long-term safety data beyond trial periods still accumulating. Cost and accessibility remain barriers for many patients. Does not address non-responders to anti-CGRP therapy.
Questions This Raises
- ?What percentage of migraine patients do not respond to anti-CGRP antibodies, and why?
- ?Are there long-term safety concerns with sustained CGRP blockade?
- ?How do these antibodies compare head-to-head in effectiveness and tolerability?
Trust & Context
- Key Stat:
- 2nd leading cause of disability Migraine affects millions globally, making effective prevention a major public health priority
- Evidence Grade:
- Strong — reviews multiple Phase 2 and 3 randomized controlled trials with consistent positive results across all four antibodies.
- Study Age:
- Published in 2020; all four antibodies have since received FDA approval and real-world data continues to accumulate.
- Original Title:
- Calcitonin Gene-Related Peptide Antagonists as a Savior in Episodic and Chronic Migraine: A Review.
- Published In:
- Cureus, 12(6), e8711 (2020)
- Authors:
- Pervez, Hira, Khemani, Lavina, Khan, Mahrukh A, Seedat, Ahmed M, Roshan, Fnu
- Database ID:
- RPEP-05063
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is CGRP and why does it matter for migraines?
CGRP (calcitonin gene-related peptide) is a signaling molecule released during migraines that causes blood vessel dilation and pain signaling in the brain. Blocking it can prevent migraine attacks from starting.
How are these antibodies different from regular migraine medications?
Unlike triptans (which treat attacks in progress) or repurposed drugs like beta-blockers, these antibodies specifically target the migraine mechanism and are given as monthly or quarterly injections for prevention.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05063APA
Pervez, Hira; Khemani, Lavina; Khan, Mahrukh A; Seedat, Ahmed M; Roshan, Fnu. (2020). Calcitonin Gene-Related Peptide Antagonists as a Savior in Episodic and Chronic Migraine: A Review.. Cureus, 12(6), e8711. https://doi.org/10.7759/cureus.8711
MLA
Pervez, Hira, et al. "Calcitonin Gene-Related Peptide Antagonists as a Savior in Episodic and Chronic Migraine: A Review.." Cureus, 2020. https://doi.org/10.7759/cureus.8711
RethinkPeptides
RethinkPeptides Research Database. "Calcitonin Gene-Related Peptide Antagonists as a Savior in E..." RPEP-05063. Retrieved from https://rethinkpeptides.com/research/pervez-2020-calcitonin-generelated-peptide-antagonists
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.